AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$MAIA

Guerrero Ramiro purchased $2K of MAIA

Guerrero Ramiro purchased 1,794 shares of MAIA Biotechnology, Inc. (MAIA) at $1.33 on 2026-08-24.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Aug 26, 2026, 11:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Neutral
high confidence
Mentioned
$MAIA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The transaction is modest and unlikely to move the stock significantly, but it adds to the insider buying record.

02

Market read

Limited relevance; primarily of interest to investors tracking insider activity.

03

What to watch

Potential upcoming clinical trial data or partnership not disclosed yet.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider trades; this filing reports a director's purchase of MAIA shares.

Company-level read

Ticker impact

$MAIANeutralHigh confidence
Context

Director Guerrero Ramiro bought 1,794 shares of MAIA at $1.33, increasing his stake to 601,911 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The purchase is under $5k and represents a routine insider transaction; markets typically view such small buys as low significance.

Market effects

Sector

Negligible effect on biotech sector; no broader industry signal.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider buys can precede larger moves if management anticipates upcoming catalyst.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    US-listed biotech company (ticker MAIA).

  • Insider
    Guerrero Ramiro

    Director of MAIA who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min